Alexei Chemiakine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexei Chemiakine has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Vincenzo Alessandro Gennarino
Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY, USA
2 shared publications - Colton J. Treadway
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
1 shared publication Ella Doron‐Mandel
Department of Biological Sciences, Columbia University, New York, NY, USA
1 shared publicationMarko Jovanovic
Department of Biological Sciences, Columbia University, New York, NY, USA
1 shared publicationMaximilian Cabaj
Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY, USA
1 shared publication- Nicholas Gene Brown
Department of Pharmacology, University of North Carolina, Chapel Hill, USA
1 shared publication
Latest Publications
- Open Access
- 18 April 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (11) , e112721
Dosage sensitivity to Pumilio1 variants in the mouse brain reflects distinct molecular mechanisms
Different mutations in the RNA‐binding protein Pumilio1 (PUM1) cause divergent phenotypes whose severity tracks with dosage: a mutation that reduces PUM1 levels by 25% causes late‐onset ataxia, whereas haploinsufficiency causes developmental delay and seizures. Yet PUM1 targets are derepressed to equal degrees in both cases, and the more severe mutation does not hinder PUM1's RNA‐binding ability. We therefore considered the possibility that the severe mutation might disrupt PUM1 interactions, and identified PUM1 interactors in the murine brain. We find that mild PUM1 loss derepresses PUM1‐specific targets, but the severe mutation disrupts interactions with several RNA‐binding proteins and the regulation of their targets. In patient‐derived cell lines, restoring PUM1 levels restores these interactors and their targets to normal levels. Our results demonstrate that dosage sensitivity does not always signify a linear relationship with protein abundance but can involve distinct mechanisms. We propose that to understand the functions of RNA‐binding proteins in a physiological context will require studying their interactions as well as their targets.
- 18 April 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (11) , e112721
Open AccessDosage sensitivity to Pumilio1 variants in the mouse brain reflects distinct molecular mechanisms
Different mutations in the RNA‐binding protein Pumilio1 (PUM1) cause divergent phenotypes whose severity tracks with dosage: a mutation that reduces PUM1 levels by 25% causes late‐onset ataxia, whereas haploinsufficiency causes developmental delay and seizures. Yet PUM1 targets are derepressed to equal degrees in both cases, and the more severe mutation does not hinder PUM1's RNA‐binding ability. We therefore considered the possibility that the severe mutation might disrupt PUM1 interactions, and identified PUM1 interactors in the murine brain. We find that mild PUM1 loss derepresses PUM1‐specific targets, but the severe mutation disrupts interactions with several RNA‐binding proteins and the regulation of their targets. In patient‐derived cell lines, restoring PUM1 levels restores these interactors and their targets to normal levels. Our results demonstrate that dosage sensitivity does not always signify a linear relationship with protein abundance but can involve distinct mechanisms. We propose that to understand the functions of RNA‐binding proteins in a physiological context will require studying their interactions as well as their targets.
- Open Access
- 15 March 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (2) , 101232
Determining the effects of loss of function mutations in human cell lines
- 15 March 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (2) , 101232
Open AccessDetermining the effects of loss of function mutations in human cell lines